Healthcare and Therapy Solutions Market Insight, Size, Share, Growth, Up-To-Date Key Trends, Regional Outlook, and Forecast - 2030
Price : US$ 3,000 | Date : Jul 2023 |
Category : Healthcare and Pharmaceuticals | Pages : 134 |
The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market is set to witness immense growth during the forecast period 2022-2028. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufacturers/players/vendors analysis, segments & sub-segments, and forecast. The report also focuses on market drivers, challenges (current and future), revenue growth, future roadmap, standardization, deployment models, and forecast analysis.
Overview:
The recombinant adeno-associated virus (AAV) is an exciting new gene delivery vector. The development of this vector was facilitated by an understanding of the biology of adeno-associated viruses. During the generation of viral vectors, several molecular interactions take place, influencing how the viral genome is replicated and the purpose for which it is delivered. To better understand AAV, a brief review of the biology of this virus is provided. While the recombinant adeno-associated virus is widely used in gene therapy research and is the basis for several FDA-approved gene therapies, it is associated with a decreased dendritic complexity in the mammalian cortex. It is not limited to a particular serotype and occurs at experimentally relevant titers. In addition, this effect is associated with increased cellular stress and upregulation of certain immune molecules.
The global adeno-associated virus (AAV) vectors in gene therapy market focus on six regions, such as North America, Asia Pacific, South America, Europe, the Middle East, and Africa.
Drivers:
The increasing prevalence of biotechnology companies in the world is expected to fuel the growth of the global adeno-associated virus (AAV) vectors in gene therapy market over the forecast period. For instance, according to Biotechgate, there are more than 20,000 biotechnology companies in the world. AAV is classified into two serotypes: AAV2 and AAV5. Both have high amino acid homology, and one of them can form a viral capsid. The capid proteins of these two serotypes are used to form the virion shell. This helps in the transduction of AAV into cell lines. In addition, a process called transcapsidation is also used to enhance AAV transduction, where the ITR gene of one serotype is packaged in the capsid of another serotype. The recombinant adeno-associated virus (AAV) is a promising viral vector for gene transfer. The AAV genome is very large and can be scaled up in cultures. However, contamination with adenovirus is undesirable. The best solution to avoid this problem is to use a transient-transfection method, which generates high-titer AAV vectors without any adenovirus contamination. Moreover, increasing research and developments related to gene therapy are estimated to enhance the growth of the global adeno-associated virus (AAV) vectors in gene therapy market.
Restraints:
Less awareness related to the adeno-associated virus is expected to hinder the growth of the global adeno-associated virus (AAV) vectors in gene therapy market.
Regional Insights:
In regions, North America is expected to hold a major share of the global adeno-associated virus (AAV) vectors in gene therapy market, owing to the high prevalence of biotechnology companies in the region. For instance, according to the American Biotechnology Association, in 2021, there were around 6,653 biotech companies in the United States. Moreover, the Asia Pacific is estimated to witness significant growth in the global adeno-associated virus (AAV) vectors in gene therapy market owing to the high investments in the biotechnology sector, focusing mainly on gene therapies.
Competitive Section:
Key players operating in the global adeno-associated virus (AAV) vectors in gene therapy market include Poseida Therapeutics, Inc., AGTC (Applied Genetic Technologies Corporation), Mustang Bio, Sangamo Therapeutics, Cellectis, Celgene Corporation (A Bristol-Myers Squibb Company), Gensight Biologics S.A., Uniqure N.V., Shanghai Sunway Biotech Co., Ltd., Sibiono Genetech Co., Ltd., Human Stem Cells Institute, Dynavax Technologies, Jazz Pharmaceuticals Plc, Bluebird Bio, Inc., Anges, Inc., AGC Biologics, Spark Therapeutics, Inc., Orchard Therapeutics Plc., Novartis AG, Amgen, Inc., Gilead Sciences, Inc., Sarepta Therapeutics, and Biogen.
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market Dynamics:
This market study estimates the market size in terms of both value (million USD) and volume (K Units). The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market report analyses market trends based on historical data and the latest developments. It provides both qualitative and quantitative data on the elements that will shape the market's growth from 2022 to 2028. The market capacity and consumption potential of major companies are discussed in this research report. Furthermore, it concentrates on prominent regions (Latin America, Europe, Asia Pacific, Africa, and the Middle East). Also, the report evaluates COVID-19's impact on the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market.
Companies profiled in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market report include:
The report covers extensive competitive intelligence which includes the following data points:
⇨ Business Overview
⇨ Business Model
⇨ Financial Data
⇨ Financial – Existing
⇨ Financial – Funding
⇨ Product/Service Segment Analysis and specification
⇨ Recent Development and Company Strategy Analysis
⇨ SWOT Analysis
Segmentation by Type:
The type segment contributed the largest share to the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market in 2021; this segment is projected to grow at the highest CAGR from 2022 to 2028.
Segmentation by Application:
An end-use industry is projected to grow at the highest CAGR during the forecast period, due to rapid development in emerging economies North America, APAC, MEA, Europe, and ROW.
Key Benefits for Stakeholders:
Reasons to Purchase Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market Report:
Research Methodology:
To estimate and validate the size of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market and many other dependent submarkets in the overall market, both top-down and bottom-up methodologies are utilized. Key players in the market have been identified through secondary research and their market shares have been determined through primary and secondary research. Secondary sources and verified primary sources were used to determine all percentage share splits and breakdowns.
* Browse 15 Market Data Tables and 32 Figures on “Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market Market” – Forecast to 2028.
Price : US$ 3,000 | Date : Jul 2023 |
Category : Healthcare and Pharmaceuticals | Pages : 134 |
Price : US$ 3,000 | Date : Jul 2023 |
Category : Healthcare and Pharmaceuticals | Pages : 125 |
Price : US$ 3,000 | Date : Jun 2023 |
Category : Healthcare and Pharmaceuticals | Pages : 144 |
Price : US$ 3,000 | Date : Jun 2023 |
Category : Healthcare and Pharmaceuticals | Pages : 167 |
Price : US$ 3,000 | Date : Jun 2023 |
Category : Healthcare and Pharmaceuticals | Pages : 162 |
In search of customized market research solution? We are here to help you. Contact us.